NASDAQ:CDLXCardlytics Stock Price, Forecast & News

$79.86

+1.74 (+2.23 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$78.51

Now: $79.86▼

$85.41

50-Day Range

$39.84

MA: $54.76▼

$78.12

52-Week Range

$22.70

Now: $79.86▼

$107.50

Volume906,764 shs

Average Volume985,681 shs

Market Capitalization$2.15 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.55

Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. It also provides solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Beat the Market (BTM) Rank^™

2.1 Analyst's Opinion

Consensus Rating
Cardlytics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $48.50, Cardlytics has a potential downside of 39.3% from its current price of $79.86.
Amount of Analyst Coverage
Cardlytics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.2 Community Rank

Outperform Votes
Cardlytics has received 186 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cardlytics has received 238 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cardlytics has received 56.13% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cardlytics and other stocks. Vote “Outperform” if you believe CDLX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CDLX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cardlytics does not currently pay a dividend.
Dividend Growth
Cardlytics does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cardlytics insiders have bought 162.02% more of their company's stock than they have sold. Specifically, they have bought $28,636,797.00 in company stock and sold $10,929,358.00 in company stock.
Percentage Held by Insiders
Only 6.50% of the stock of Cardlytics is held by insiders.
Percentage Held by Institutions
83.51% of the stock of Cardlytics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Cardlytics are expected to grow in the coming year, from ($1.42) to ($0.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cardlytics is -79.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cardlytics is -79.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cardlytics has a P/B Ratio of 12.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.79 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Computer programming, data processing, & other computer related

Sub-IndustryN/A

SectorBusiness Services

Current SymbolNASDAQ:CDLX

Previous Symbol

CUSIPN/A

CIK1666071

Webwww.cardlytics.com

Phone888-798-5802

Debt

Debt-to-Equity RatioN/A

Current Ratio2.91

Quick Ratio2.91

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$210.43 million

Price / Sales10.24

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.28 per share

Price / Book12.72

Profitability

EPS (Most Recent Fiscal Year)($0.75)

Net Income$-17,140,000.00

Net Margins-11.08%

Return on Equity-19.42%

Return on Assets-11.53%

Miscellaneous

EmployeesN/A

Outstanding Shares26,970,000

Market Cap$2.15 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableNot Optionable

Receive CDLX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.

Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

How has Cardlytics' stock been impacted by COVID-19 (Coronavirus)?

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CDLX stock has increased by 74.3% and is now trading at $79.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cardlytics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cardlytics.

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cardlytics.

How were Cardlytics' earnings last quarter?

Cardlytics Inc (NASDAQ:CDLX) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. The firm had revenue of $45.51 million for the quarter, compared to the consensus estimate of $42.97 million. Cardlytics had a negative return on equity of 19.42% and a negative net margin of 11.08%. The company's quarterly revenue was up 26.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.23) earnings per share. View Cardlytics' earnings history.

What price target have analysts set for CDLX?

7 brokers have issued 1 year price objectives for Cardlytics' shares. Their forecasts range from $26.00 to $55.00. On average, they anticipate Cardlytics' stock price to reach $48.50 in the next twelve months. This suggests that the stock has a possible downside of 39.3%. View analysts' price targets for Cardlytics.

Has Cardlytics been receiving favorable news coverage?

News coverage about CDLX stock has trended positive on Saturday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cardlytics earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutCardlytics.

Who are some of Cardlytics' key competitors?

Some companies that are related to Cardlytics include Stars Group (TSG), Weibo (WB), 58.com (WUBA), GDS (GDS), InterXion (INXN), Livongo Health (LVGO), Switch (SWCH), HUYA (HUYA), Medallia (MDLA), DouYu International (DOYU), SVMK (SVMK), Tripadvisor (TRIP), Pluralsight (PS), Sabre (SABR) and Internet Initiative Japan (IIJIY). View all competitors.

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), Trade Desk (TTD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Caterpillar (CAT), Roku (ROKU), Micron Technology (MU), Netflix (NFLX), Square (SQ) and Walt Disney (DIS).

Who are Cardlytics' key executives?

Cardlytics' management team includes the following people:

Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 56)
Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 49)
Mr. David Evans, CFO & Head of Corp. Devel.
Mr. Sathish Gaddipati, Chief Technology Officer (Age 52)
Mr. Kirk L. Somers, Chief Legal & People Officer (Age 54)

When did Cardlytics IPO?

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include CAS Investment Partners LLC (14.65%), Wellington Management Group LLP (4.69%), BlackRock Inc. (4.43%), Grantham Mayo Van Otterloo & Co. LLC (3.00%), JS Capital Management LLC (2.02%) and Frontier Capital Management Co. LLC (2.05%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman. View institutional ownership trends for Cardlytics.

Which institutional investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Deutsche Bank AG, Driehaus Capital Management LLC, BNP Paribas Arbitrage SA, Invesco Ltd., Morgan Stanley, Morgan Stanley, and Nuveen Asset Management LLC. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes, and Tony Weisman. View insider buying and selling activity for Cardlytics.

Which institutional investors are buying Cardlytics stock?

CDLX stock was acquired by a variety of institutional investors in the last quarter, including CAS Investment Partners LLC, JPMorgan Chase & Co., Grantham Mayo Van Otterloo & Co. LLC, THB Asset Management, Rockefeller Capital Management L.P., Harspring Capital Management LLC, Frontier Capital Management Co. LLC, and Lord Abbett & CO. LLC. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen. View insider buying and selling activity for Cardlytics.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $79.86.

How big of a company is Cardlytics?

Cardlytics has a market capitalization of $2.15 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

What is Cardlytics' official website?

The official website for Cardlytics is www.cardlytics.com.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff